A Study of Multiple Doses of Vesnarinone in Advanced HIV Disease
Phase 1
Completed
- Conditions
- HIV Infections
- Registration Number
- NCT00002337
- Lead Sponsor
- Otsuka America Pharmaceutical
- Brief Summary
To evaluate the safety and tolerability of four doses of oral vesnarinone in patients with advanced HIV disease.
- Detailed Description
Fourteen patients per dose level receive vesnarinone at 1 of 4 doses for 12 weeks. At least seven patients at a given dose level must have completed 4 weeks of treatment before dose is escalated in subsequent patients.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 56
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms of vesnarinone affect HIV viral replication and immune response pathways?
How does vesnarinone compare to standard antiretroviral therapies in advanced HIV disease outcomes?
Which biomarkers correlate with vesnarinone efficacy in patients with advanced HIV disease?
What adverse events are associated with vesnarinone in phase I trials for HIV treatment?
Are there combination therapies involving vesnarinone and other HIV drugs under investigation by Otsuka Pharmaceutical?
Trial Locations
- Locations (1)
AIDS Research Consortium of Atlanta
🇺🇸Atlanta, Georgia, United States
AIDS Research Consortium of Atlanta🇺🇸Atlanta, Georgia, United States